At a glance
ClinicalIndex Comparison RecordN/ACompleted· 109 enrolled
Drug / intervention
Procrit (epoetin alfa)drug
Likely dose
Procrit (epoetin alfa) 40,000 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Study of Procrit Versus No Procrit in Patients With Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
In Brief
A clinical study evaluating Procrit (epoetin alfa) for Leukemia. Completed, enrolled 109 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if Procrit (epoetin alfa) will decrease the need for blood transfusions in patients with Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma (LL), or Burkitt's who are receiving chemotherapy. Another goal is to study the remission rates in patients with cancer who have received treatment with epoetin alfa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2003
First PostedApr 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedApr 6, 2010
Enrollment StartMar 1, 2003
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 16.2 years ago
Interventions
Procrit (epoetin alfa)drug
Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).